NCT02071160View on ClinicalTrials.gov

Melatonin for Neuroprotection Following Perinatal Asphyxia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Perinatal Asphyxia
Interventions
DRUG

Melatonin

Melatonin is administered to the melatonin/hypothermia group (n=15) in a dose of 10 mg/kg daily for a total of 5 doses starting immediately at enrollment. Melatonin tablets (1 or 3 mg/tablet) (Puritan's Pride,Oakdale, NY, USA) are crushed, then dissolved in 5-10 ml of distilled water , then administered via an orogastric tube.

Trial Locations (1)

Unknown

Tanta University Children's Hospital, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT02071160 - Melatonin for Neuroprotection Following Perinatal Asphyxia | Biotech Hunter | Biotech Hunter